Solventum (NYSE:SOLV) Downgraded to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Solventum (NYSE:SOLV) from a strong-buy rating to a buy rating in a report published on Sunday morning.

SOLV has been the subject of several other research reports. Argus raised Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target for the company in a report on Tuesday, July 1st. KeyCorp initiated coverage on Solventum in a report on Friday, June 6th. They set a “sector weight” rating for the company. Piper Sandler reissued an “overweight” rating and set a $94.00 price target (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. Wells Fargo & Company boosted their price target on Solventum from $75.00 to $79.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Finally, Morgan Stanley raised Solventum from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $80.00 to $103.00 in a research note on Tuesday, July 15th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Solventum has an average rating of “Hold” and a consensus target price of $85.75.

Solventum Stock Up 2.0%

SOLV stock opened at $73.46 on Friday. Solventum has a 1-year low of $59.35 and a 1-year high of $85.92. The business has a fifty day moving average price of $73.79 and a 200-day moving average price of $72.84. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The stock has a market capitalization of $12.74 billion, a P/E ratio of 34.01, a P/E/G ratio of 1.78 and a beta of 0.52.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. The company had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.Solventum’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities analysts forecast that Solventum will post 6.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Solventum

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Clarity Asset Management Inc. bought a new position in Solventum during the fourth quarter valued at approximately $25,000. Rossby Financial LCC bought a new position in Solventum during the first quarter valued at approximately $25,000. Strengthening Families & Communities LLC boosted its stake in Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares during the last quarter. CYBER HORNET ETFs LLC bought a new position in Solventum during the second quarter valued at approximately $28,000. Finally, Raiffeisen Bank International AG bought a new position in Solventum during the fourth quarter valued at approximately $29,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.